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Background: It has been suggested that the adipokine resistin links obesity and insulin resistance, although how
resistin acts on muscle metabolism is controversial. We aimed to quantitatively analyse the effects of resistin on the
glucose metabolic flux profile and on insulin response in L6E9 myotubes at the metabolic level using a tracer-based
metabolomic approach and our in-house developed software, Isodyn.
Results: Resistin significantly increased glucose uptake and glycolysis, altering pyruvate utilisation by the cell. In the
presence of resistin, insulin only slightly increased glucose uptake and glycolysis, and did not alter the flux profile
around pyruvate induced by resistin. Resistin prevented the increase in gene expression in pyruvate
dehydrogenase-E1 and the sharp decrease in gene expression in cytosolic phosphoenolpyruvate carboxykinase-1
induced by insulin.
Conclusions: These data suggest that resistin impairs the metabolic activation of insulin. This impairment cannot
be explained by the activity of a single enzyme, but instead due to reorganisation of the whole metabolic
flux distribution.
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Obesity is increasing to epidemic proportions [1,2],
starting from young ages [3,4], and is associated with an
increase in the prevalence of type-2 diabetes mellitus
(T2DM) throughout the world [2,5]. In recent years, active
participation of immune cells in obesity and T2DM has
become evident [6,7]. This chronic activation of the innate
immune system can lead to insulin resistance (IR), im-
paired tolerance to glucose and, eventually, T2DM [8,9].
Adipose tissue produces a vast array of adipocyte-
derived factors (“adipokines”) that regulate the metabol-
ism, inflammation and body mass [10,11]. One of these* Correspondence: martacascante@ub.edu
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unless otherwise stated.adipokines, resistin, belongs to a family of cysteine-rich
proteins shown to be involved in inflammation and al-
tered insulin sensitivity in rodents [12,13]. Resistin is
produced from adipose tissue in rodents whereas, in
humans, it is secreted by the mononuclear lymphocytes
and stromal cells within adipose tissue [14,15]. Studies
in humanised resistin mice suggest that, even though the
site of resistin production differs between species, hu-
man resistin exacerbates inflammation in white adipose
tissue and contributes to IR, thereby impairing its nor-
mal effects [16,17].
IR is defined as the genetic or learned inability of tar-
get tissues to respond normally to the action of circulat-
ing hormones. It has been described in skeletal muscle
but also in liver and adipose tissues [18]. Some studies
have shown that resistin affects glucose transport and
insulin-stimulated oxidation of glucose in L6 skeletal
muscle cells [19-22]. It also decreases the uptake andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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synthase kinase-3-β, as well as insulin-stimulated insulin
receptor substrate-1 (IRS-1) tyrosine phosphorylation
[19,22] in the same cell line. Furthermore, high levels of
resistin in rats leads to IR involving impaired insulin sig-
nalling in skeletal muscle, liver and adipose tissues,
resulting in glucose intolerance, hyperinsulinemia and
hypertriglyceridemia [24]. These observations link resis-
tin in muscle-cell metabolism to IR.
Changes in the metabolome (i.e., the whole set of me-
tabolites) have been described as the “ultimate” response
of an organism to various events, such as genetic alter-
ations as well as disease-based or environmental influ-
ences [25]. However, the metabolome is dynamic and
metabolites are transformed continuously in the cell.
Comprehensive characterisation of the metabolic net-
works and their functional states requires quantitative
knowledge of intracellular metabolic fluxes. These intra-
cellular fluxes can be quantified by analysing incorpor-
ation of labelled substrates in metabolic products using
appropriate bioinformatic tools [26].
Skeletal muscle is considered to be the main tissue in-
volved in the maintenance of glucose homeostasis because
its contribution to glucose uptake is ≈ 75% of the total
contribution of peripheral tissues [27], and it is the main
tissue responsible for insulin-dependent glucose use. Also,
pyruvate homeostasis-related fluxes in skeletal muscle play
a critical part in glucose homeostasis [28-32]. A better un-
derstanding of how these fluxes work together in muscle
cells is needed to understand this process.
The aim of the present study was to examine the effect
of resistin on the central carbon metabolic network of rat
skeletal muscle cells, and to ascertain how resistin alters
the response of muscle cells to insulin at the metabolic
level. We used [1,2-13C2]-glucose as a tracer, analysed iso-
topomer distributions by gas cromatography (GC) coupled
with mass spectrometry (MS), and quantified metabolic
fluxes using Isodyn software [26,33-36]. In the model of
the glucose metabolic network in skeletal muscle we in-
cluded the glycolytic pathway and pentose phosphate
pathway (PPP). Pyruvate dehydrogenase complex (PDC)-,
phosphoenolpyruvate carboxykinase (PEPCK)- and
pyruvate carboxylase (PC)-catalysed reactions were also
included to account for pyruvate homeostasis-related
fluxes. Resistin-induced alterations in the profile of
metabolic fluxes of rat skeletal muscle cells were identi-
fied, and were complemented by analyses of the expres-
sion of certain genes.
The study presented here offers a wider vision than pre-
viously published of the metabolic reorganisation that
resistin induces in rat skeletal muscle cells and in the
metabolic response of these cells to insulin. Our observa-
tions provide new data for a more precise understanding
of the effect of resistin on metabolic-network adaptationsof skeletal muscle cells, and help to explain the role of
resistin in the IR described in myocytes. Our work reveals
the importance of tackling the study of complex biological
systems from a systems-biology point of view to fully
understand multifactorial diseases and identify new thera-
peutic targets.
Results
For analyses of the effect of resistin on glucose metabol-
ism and on the metabolic response of muscle cells to in-
sulin, L6E9 myotubes were pretreated for 8 h with or
without resistin (100 nM). After preincubation, myo-
tubes were incubated for a further 6 h with glucose
(10 mM) that was 50% enriched in [1,2-13C2]-glucose in
the absence or presence of 100 nM insulin and in the
continued presence or absence of resistin.
After 6 h of incubation, glucose consumption, lactate
production, intracellular levels of glycogen and glucose-
6-phosphate (G6P) were determined (Table 1), as were
the mass-isotopomer distributions in glucose and lactate
from the incubation medium, as well as glycogen glucose
and ribose isolated from RNA in cell pellets (Table 2).
Analyses of the obtained data by Isodyn determined the
distribution of the metabolic flux profile of L6E9 myo-
tubes under various incubation conditions (Table 3).
Figure 1 summarises the qualitative changes in metabo-
lites and fluxes.
Basal metabolic flux profile of L6E9
Isodyn quantified the metabolic-flux distribution in
L6E9 myotubes incubated in the presence of glucose
(10 mM) and in the absence of insulin or resistin
(Table 3, first column). Under this incubation condition,
cells had a glucose phosphorylation of 1.500 nmol · mL–1 ·
min–1. This flux was maintained throughout the subse-
quent steps of “upper glycolysis” (of which flux-1 is repre-
sentative) until the split of fructose-1,6-bisphosphate into
two triose-phosphates by aldolase. From this reaction on-
wards, the glycolytic flux (hereafter referred to as “lower
glycolysis”) increased twofold (as shown in flux-3). Add-
itionally, the flux across the oxidative branch of the PPP
was around eight-times lower than the upper glycolytic
flux. With regard to glycogen metabolism, glycogen phos-
phorylase (GP) (flux-4) and glycogen synthase (GS) (flux-5)
were active, and glycogen recycling was estimated to be ≈
2% of the total glucose phosphorylation flux.
However, the most important contribution of Isodyn
for interpretation of experimental data was the possibil-
ity of flux quantification around the final steps of lower
glycolysis and the tricarboxylic acid (TCA) cycle. In that
regard, Isodyn revealed that ≈ 49% of phosphoenolpyr-
uvate (PEP) and pyruvate entered the TCA cycle through
the reactions catalysed by PDC (flux-6) or PC (flux-7),
with a relative PDC:PC ratio of 8:1. Around 44% of the
Table 1 Biochemical parameters in L6E9 myotubes after different incubations with resistin and/or insulin
Incubation condition
Ins- Ins+
Res- Res+ Res- Res+
Glucose consumption (mM) 0.50 ± 0.04 0.61 ± 0.06* 0.78 ± 0.03** 0.70 ± 0.09
Lactate production (mM) 0.48 ± 0.01 0.56 ± 0.02** 0.75 ± 0.06** 0.79 ± 0.02†
Glycogen (μg glucose/mg prot) 9.88 ± 1.99 9.97 ± 0.98 11.34 ± 0.59 11.62 ± 1.21
Glucose-6-phosphate (nmol/mg prot) 0.92 ± 0.14 1.44 ± 0.28 2.30 ± 0.29** 2.10 ± 0.19†
L6E9 myotubes were treated (Res+) or not treated (Res–) with 100 nM resistin for 8 h and then incubated for 6 h in the absence (Ins–) or presence (Ins+) of 100
nM insulin. Glucose consumption, lactate production, and intracellular contents of glycogen and glucose-6-phosphate were determined as described in the
Methods section. Results are the mean ± standard deviation (n = 3). Units of glucose consumption and lactate production refer to the volume of the incubation
medium. (*) indicates p < 0.05 and (**) p < 0.01 compared with the condition of neither resistin nor insulin. (†) indicates p < 0.05 compared with the L6E9
myotubes treated only with resistin.
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put of lactate towards the cell culture medium (flux-8),
and pyruvate cycling flux (flux 9). This finding accounted
for the fact that feedback of molecules from the TCA cycle
back towards the PEP–pyruvate pool was around ten-
times higher than the flux of the TCA cycle towards cit-
rate synthesis (flux-10).Table 2 Mass isotopomer distribution of lactate, glycogen
and ribose after incubations with resistin and/or insulin
Mass isotopomer distributions (%)
Incubation condition
Ins- Ins+
Res- Res+ Res- Res+
Lactate
m0 88.56 ± 0.98 88.74 ± 0.25 87.68 ± 0.22 87.63 ± 0.17
m1 0.70 ± 0.34 0.48 ± 0.11 0.63 ± 0.06 0.52 ± 0.14
m2 10.53 ± 0.30 10.85 ± 0.15 11.69 ± 0.05* 11.78 ± 0.11
m3 0.21 ± 0.63 0.07 ± 0.18 0.00 ± 0.11 0.07 ± 0.13
Glycogen
m0 67.28 ± 0.65 69.20 ± 1.41 65.14 ± 1.08 64.48 ± 0.45
m1 0.29 ± 0.03 0.36 ± 0.14 0.96 ± 0.10 0.84 ± 0.10
m2 31.78 ± 0.74 29.91 ± 1.02 33.20 ± 1.18 33.78 ± 0.76
m3 0.53 ± 0.19 0.43 ± 0.28 0.43 ± 0.07 0.60 ± 0.20
m4 0.00 ± 0.02 0.00 ± 0.06 0.17 ± 0.05 0.15 ± 0.02
Ribose
m0 96.13 ± 0.55 94.28 ± 0.76 94.47 ± 0.48 92.83 ± 1.18
m1 1.34 ± 0.23 1.45 ± 0.11 2.56 ± 0.14 2.97 ± 0.15
m2 0.68 ± 0.19 1.14 ± 0.16* 1.18 ± 0.09* 1.40 ± 0.23
m3 1.17 ± 0.63 1.56 ± 0.58 0.87 ± 0.17 1.14 ± 0.32
m4 0.50 ± 0.44 1.17 ± 0.22* 0.61 ± 0.14 1.17 ± 0.41
L6E9 myotubes were treated (Res+) or not treated (Res–) with 100 nM resistin
for 8 h and then incubated for 6 h with 10 mM glucose, 50%-enriched in
[1,2-13C2]-glucose in the absence (Ins–) or presence (Ins+) of 100 nM insulin.
Mass isotopomer distributions at the end of incubations were determined, as
described in the Methods section. Results are the mean± standard deviation (n = 3).
(*) indicates p < 0.05 compared with the condition of neither resistin nor insulin.Effect of resistin on the metabolic flux profile of L6E9
L6E9 myotubes treated with 100 nM resistin showed 13%
higher flux of glucose phosphorylation (1.700 nmol · mL–1 ·
min–1). Fitting of the experimental data from this incuba-
tion condition using Isodyn (Table 3, second column) sug-
gested that resistin increased the glycolytic flux, with a
significant increase in the glucose phosphorylation flux, and
a proportional increase of glycolytic fluxes. Resistin induced
changes in the non-oxidative branch of the PPP (data not
shown), but the relative flux through the oxidative branch
(flux-2) was unchanged. Glycogen recycling-related fluxes
(fluxes 4 and 5) remained unchanged, as indicated by the
fact that the net 13C incorporation in glycogen was very
similar to the control condition.
Moreover, resistin increased lactate production (Table 1),
which translated to an increase in the lactate dehydrogen-
ase flux (flux-8), though it was not significant. The most
significant metabolic change after Isodyn fitting was ob-
served in the PDC-related flux (flux-6), which was in-
creased significantly (99% confidence). If we consider the
relative ratios of the two main pyruvate incorporation
fluxes (PDC and PC, fluxes 6 and 7, respectively), there
was an increase of the PDC prevalence to 20:1. This find-
ing was also supported by the level of pyruvate dehydro-
genase kinase isozyme 4 (Pdk4) mRNA (Figure 2E), and
was observed as a trend in the level of pyruvate dehydro-
genase Pdha1 mRNA (Figure 2C). Despite the large
change in this ratio, the effect on fluxes in the TCA cycle
was almost negligible even though there was an increase
in the acetyl-CoA output flux (flux-14). The pyruvate cyc-
ling flux was unchanged by resistin treatment alone, which
was supported by the level of Pepck mRNA (Figure 2H).
Effect of resistin on the metabolic response of insulin in
L6E9 myotubes
Having investigated the alterations caused by resistin on
the metabolic profile of L6E9 myotubes, we examined its
effect on the metabolic response of myotubes to insulin.
First we ascertained if resistin affected stimulation of
insulin-induced glucose transport. Thus, induction of 2-
Table 3 Metabolic fluxes adjusted by Isodyn for different incubation conditions
Metabolic fluxes (nmol · mL-1 · min-1)
Incubation condition
Ins – Ins +
Flux num Flux reaction Res – Res + Res – Res +
Median [min–max] Median [min–max] Median [min–max] Median [min–max]
0 Glucose phosphorylation 1.500 [1.500–1.500] 1.700** [1.700–1.700] 2.300** [2.300–2.300] 1.975†† [1.975–1.975]
Glycolytic and PPP fluxes:
1 Phosphofructokinase 1.674 [1.442–3.004] 2.018 [1.679–2.586] 2.664* [2.537–2.670] 1.907 [1.874–1.919]
2 Oxidative branch of PPP 0.199 [0.196–0.199] 0.200 [0.198–0.200] 0.248** [0.246–0.298] 0.198 [0.192–0.199]
3 Pyruvate kinase 3.078 [3.026–3.262] 3.582 [2.644–4.126] 4.671** [4.573–4.873] 4.337 [4.087–4.468]
Glycogen-related fluxes:
4 Glycogen phosphorylase 0.038 [0.034–0.052] 0.034 [0.024–0.066] 0.043 [0.037–0.046] 0.032 [0.029–0.035]
5 Glycogen synthase 0.040 [0.036–0.053] 0.035 [0.024–0.067] 0.050 [0.043–0.058] 0.038 [0.034–0.040]
Pyruvate homeostasis-related fluxes:
6 Pyruvate dehydrogenase complex 1.511 [1.421–1.843] 2.354** [2.118–2.363] 2.479* [1.785–2.987] 2.125 [1.575–2.494]
7 Pyruvate carboxylase 0.200 [0.113–0.291] 0.117 [0.027–0.201] 0.197 [0.155–0.254] 0.031 [0.028–0.055]
8 Lactate dehydrogenase 1.366 [1.292–1.451] 1.511 [1.446–1.654] 2.033** [1.620–2.738] 2.192†† [1.722–2.739]
9 Pyruvate cycling 0.228 [0.200–0.377] 0.474 [0.222–0.884] 0.296 [0.264–0.389] 0.538 [0.303–0.594]
Tricarboxylic acid cycle fluxes:
10 Citrate synthase 0.022 [0.019–0.386] 0.012 [0.001–0.023] 0.099 [0.022–0.172] 0.009 [0.002–0.037]
11 Citrate - > Malate 0.035 [0.032–0.462] 0.072 [0.050–0.400] 0.185 [0.110–0.298] 0.370 [0.082–0.395]
12 Malate - > OAA 0.640 [0.481–2.088] 1.152 [0.453–3.104] 1.509 [0.780–2.413] 2.078 [0.477–3.095]
13 OAA - > Malate 0.605 [0.446–1.776] 1.080 [0.294–2.800] 1.324 [0.668–2.115] 1.708 [0.336–2.773]
14 Acetyl-CoA output 1.489 [1.313–1.625] 2.344** [2.114–2.355] 2.380** [1.760–2.851] 2.116 [1.565–2.485]
Principal fluxes of central carbon metabolism calculated in L6E9 myotubes treated (+Res) or not treated (–Res) with 100 nM resistin for 8 h and then incubated for
6 h with 10 mM glucose, 50%-enriched in [1,2-13C2]-glucose in the absence (–Ins) or presence (+Ins) of 100 nM insulin. Glucose phosphorylation flux was fixed
according to the glucose consumption measured (Table 1). Remaining fluxes are expressed by median values as well as minimum and maximum values from the
20 best flux sets. Fluxes are expressed in nmol · mL–1 · min–1, where volume is the volume of the incubation medium. χ2 values for the averages were: Ins– Res–:
11.35; Ins– Res+: 5.42; Ins + Res–: 22.50; Ins + Res+: 25.56. (**) indicates that the flux is different to the control condition with a 99% confidence interval (CI), (*)
indicates that the flux is different to the control condition with a 95% CI, and (††) indicates that the flux differs from the condition in which cells were treated
only with resistin with a 99% CI. PPP, pentose phosphate pathway; OAA, oxaloacetate.
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30 min after incubation with 100 nM insulin in L6E9
myotubes treated or not treated with 100 nM resistin.
Insulin induced an increase in 2-DG transport in L6E9
myotubes of 79.27 ± 0.04%. However, it induced an in-
crease in glucose transport in cells that had been pre-
treated with 100 nM resistin for 8 h of 48.00 ± 0.05%.
Subsequently, we analysed changes in the metabolic flux
profile induced by insulin in L6E9 myotubes treated or
not treated with 100 nM resistin.
In the absence of resistin, insulin stimulated an increase
in glucose consumption and lactate production in L6E9
myotubes. There were no changes in glycogen content,
but a 150% increase in intracellular G6P content (Table 1).
Fitting of experimental data using Isodyn (Table 3, third
column) revealed that the flux of lactate production (flux-
8) was 48% higher than that in cells not treated with insulin.
Insulin also increased the flux of glucose phosphorylation
(determined to be 2.300 nmol · mL–1 · min–1) and glycolyticfluxes (fluxes 1 and 3) by ≈ 59%, and induced a 25%
increase in the oxidative PPP flux (flux-2). Moreover, fluxes
related to glycogen metabolism (fluxes 4 and 5) did not
change significantly after insulin treatment (albeit the me-
dian values were apparently higher than in the control con-
dition). Insulin increased the flux through PDC (flux-6) by
around 1.5-fold, but did not affect the remainder of TCA
cycle-related fluxes significantly, as confirmed by the
reduction in levels of Pdk4 mRNA and the increasing ten-
dency of levels of Pdha1 mRNA (Figure 2E and C, respect-
ively). The relative ratio of PDC:PC fluxes increased from
8:1 to 13:1 after insulin treatment. Insulin also led to a
59% increase in the acetyl-CoA output fluxes.
In the presence of resistin, insulin increased the flux of
glucose phosphorylation by 16% more than when cells were
treated with resistin alone. Glycolysis fluxes did not increase
significantly compared with the resistin condition, but the
lactate dehydrogenase flux increased by 45% (flux-8). The
increase induced by resistin treatment in the oxidative PPP
No significant change 
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Figure 1 Metabolic fluxes in L6E9 myotubes not treated and treated with resistin and/or insulin. L6E9 myotubes were treated (resistin+)
or not treated (resistin–) with 100 nM resistin for 8 h and then incubated for 6 h with 10 mM glucose, 50%-enriched in [1,2-13C2]-D-glucose in the
absence or in the presence of 100 nM insulin. Fluxes were estimated using the software Isodyn. Arrow sizes indicate net fluxes in L6E9 myotubes
not treated or treated with resistin that were incubated in the absence of insulin. Colours indicate flux fold-changes in response to insulin. Fluxes
plotted are the median values from the 20 best flux sets (Table 3). Grey-coloured fluxes have not been measured. FBP, fructose-1,6-bisphosphate; Hexose-P,
glucose-6-phosphate and its isomers; Mal, malate; OAA, oxaloacetate; Pentose-P, ribose-5-phosphate and its isomers; PEP, phosphoenolpyruvate; PYR,
pyruvate; Triose-P, glyceraldehyde-3-phosphate and dihydroxyacetone phosphate.
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http://www.biomedcentral.com/1752-0509/8/109pathway was not significantly altered if cells were also
treated with insulin. Similarly, the GS and GP fluxes did
not change significantly after resistin treatment.
Interestingly, there was no change in the PDC flux
(flux-6) or the acetyl-CoA production flux (flux-14), and no
change was observed in the remainder of TCA cycle-
related fluxes. If the ratio between PDC and PC fluxes is
taken into account, it shifted from 20:1 towards 70:1 afterresistin was combined with insulin. The final metabolic
state of insulin-stimulated L6E9 did not match the one of
cells treated with resistin. Some fluxes were equal in
resistin-treated and -untreated cells: oxidative PPP flux, GS
flux, GP flux, and TCA cycle-related fluxes. Most of the
quantified fluxes were lower in resistin, but significant
changes were found only in the lactate dehydrogenase flux,
and the PDC:PC ratio.
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Figure 2 (See legend on next page.)
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(See figure on previous page.)
Figure 2 Gene expression of enzymes related to pyruvate homeostasis. L6E9 myotubes were treated (Res+) or not treated (Res–) with 100 nM
resistin for 8 h and then incubated for 6 h with 10 mM glucose in the absence (Ins–) or presence (Ins+) of 100 nM insulin. RT-qPCR monitoring of
mRNA levels of pyruvate carboxylase (Pc) (A), pyruvate kinase muscle isozyme (Pkm2) (B), pyruvate dehydrogenase E1 alpha 1 (Pdha1) (C), pyruvate
dehydrogenase kinase isozyme 2 (Pdk2) (D), pyruvate dehydrogenase kinase isozyme 4 (Pdk4) (E), cytosolic NADP-isocitrate dehydrogenase (Idh1) (F),
NADP-dependent malic enzyme (Me1) (G) and cytosolic phosphoenolpyruvate carboxykinase 1 (Pck1) (H) are shown. Results from three experiments
are expressed as the mean ± S.E.M. (*) indicates p < 0.05 and (**) p < 0.01 compared with the condition of neither resistin nor insulin. (#) indicates
p < 0.05 and (##) p < 0.01 compared with L6E9 myotubes treated only with resistin.
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http://www.biomedcentral.com/1752-0509/8/109Effect of resistin on gene expression of the enzymes
involved in the PDC, PC and pyruvate cycling fluxes in L6E9
To investigate further if the observed effects in metabolic-
flux distribution were prompted by a change in the gene
expression of any of the enzymes involved in their activ-
ities, we analysed the gene expression of several enzymes
involved in pyruvate homeostasis at the end of the four in-
cubation conditions tested.
Neither insulin, nor resistin, nor combination of the two
hormones had a significant effect on levels of pyruvate
carboxylase (Pc) mRNA or pyruvate kinase muscle iso-
zyme (Pkm2) mRNA (Figure 2A and B). However, insulin
(but not resistin) increased levels of pyruvate dehydrogen-
ase E1 (Pdha1) and decreased pyruvate dehydrogenase
kinase isozyme 2 (Pdk2) mRNA (Figure 2C and D). Pres-
ence of resistin did not alter the decrease in levels of Pdk2
mRNA caused by insulin, but prevented the increase in
levels of Pdha1 mRNA. mRNA expression of pyruvate de-
hydrogenase kinase isozyme 4 (Pdk4) decreased after
treatment with both hormones (Figure 2E), with an addi-
tive effect if both were combined. These results suggest
that resistin prevents the insulin-induced increase in
Pdha1 expression, and does not prevent the increase in
PDC activity caused by a reduction of expression of Pdk2
and Pdk4 genes.
Moreover, mRNA levels of cytosolic NADP-isocitrate
dehydrogenase (Idh1) and NADP-dependent malic en-
zyme (Me1), both causes of pyruvate cycling increasing
NADPH production, were not affected by any of the hor-
mones tested under these conditions (Figure 2F and G).
However, insulin significantly decreased (by 50%) levels of
Pck1 mRNA in the absence of resistin, but not in the pres-
ence of resistin (Figure 2H). These results suggest that
resistin prevents inhibition of expression of the Pck1 gene.
Hence, cytosolic flux in PEPCK may be active in the pres-
ence of resistin independent of the presence of insulin.
Discussion
After the discovery of several adipocyte-secreted mole-
cules (including lipid metabolites and adipokines), adipo-
cytes were recognized as part of endocrine tissue [9,11,37].
These molecules enable adipocytes to communicate with
other tissues and organs, and to regulate: the metabolism
of lipids and glucose; energy balance; insulin action; cell
proliferation. Resistin was identified as an adipokine, andit was suggested that it might link obesity and IR [12,13].
However, the role of resistin in the pathophysiology of IR
in humans and animals, and how it acts in muscle, liver
and fat, is controversial [15,16].
Here, we investigated the effect of resistin on basal
and insulin-stimulated glucose metabolism in L6E9 rat
myotubes. We used tracer-based metabolomics and our
in-house Isodyn software to analyse quantitatively meta-
bolic flux distribution in this cell line under different in-
cubation conditions. The response to insulin and other
hormone stimuli in L6E9 cells is similar to that observed
in skeletal muscle in vivo [38]. Hence, L6E9 cells are
considered to be suitable models for analyses of the ef-
fect of resistin on glucose metabolism and on the meta-
bolic response of muscle cells to insulin.
Analyses with Isodyn data provided an overview of the
central carbon metabolism of L6E9 skeletal muscle cells.
Analyses were undertaken assuming a metabolic steady
state (though not assuming an isotopic steady state), and
rapid mixing of isotopic isomers of the same metabolite
throughout different intracellular compartments. Incuba-
tion with a large excess of glucose ensured the required
glucose uptake throughout the incubation. The other con-
ditions of incubation did not change, so the assumption of
a metabolic steady state seemed reasonable. Rapid mixing
of isotopic isomers of the same species throughout the cell
is accepted for analyses of data of stable isotopes [39]. Fit-
ting of experimental data in the framework of these as-
sumptions suggested a set of metabolic fluxes underlying
the measured distributions of isotopic isomers.
The effect of insulin on L6E9 myotubes increases
glycolysis, PPP, and incorporation of pyruvate to the TCA
cycle through PDC and fatty-acid synthesis
Our results suggested that L6E9 myotubes were highly
glycolytic, with active synthesis and degradation of glyco-
gen, and showed TCA-cycle activity and acetyl-CoA out-
put. Oxidative PPP was weakly active in this cell type.
Furthermore, use of the same tools revealed that insulin
activated the uptake and phosphorylation of glucose, gly-
colysis and lactate production, the oxidative branch of the
PPP, pyruvate incorporation towards the TCA cycle and
increased acetyl-CoA output (which is used for fatty-acid
synthesis). We observed that insulin altered the ratio be-
tween PDC and PC fluxes by increasing the PDC flux
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Pdk2 and Pdk4 mRNA. The effects of insulin on the meta-
bolic flux distribution of L6E9 myotubes reported in the
present study correlate with the known activation of PDC
by profound suppression of Pdk4 expression in skeletal
muscle [40], inhibition of expression of the Pck1 gene, and
the increase in glucose uptake and lactate production ob-
served using other approaches [38,41].
The effect of resistin on L6E9 myotubes increases
glycolysis and fatty-acid synthesis and alters the ratio
between PDC and PC, tilting it towards direct
incorporation of pyruvate through PDC
Our results revealed that, in the absence of insulin, resis-
tin activated glucose phosphorylation and the glycolytic
pathway. Also, resistin did not affect the glycogen con-
tent in skeletal muscle. Even though enrichment of the
glycogen label (reflected in the m2 values of the glyco-
gen molecule) was not significantly different to the con-
trol condition, the tendency was for glycogen-related
fluxes to be lower, a result that was in accordance with
other works [22]. Furthermore, our approach showed that,
even though many of the TCA-cycle fluxes remained un-
changed, the ratio between the PDC and PC fluxes was sig-
nificantly altered, effectively increasing the incorporation of
pyruvate through PDC into mitochondria (as suggested by
the reduction observed in levels of Pdk4 mRNA). PC activ-
ity is finely regulated by mechanisms such as allosteric acti-
vation by acetyl carnitine, which was not tested in this
study. The acetyl-CoA output for fatty-acid synthesis was
also increased after resistin treatment, which would explain
the higher flux towards the TCA cycle.
The effect of resistin impairs normal insulin
metabolic actions
We showed that resistin affects the normal metabolic re-
sponse of L6E9 myotubes to insulin. Thus, the increase in
glucose uptake and glycolytic flux induced by insulin was
lower than that observed in resistin-treated myotubes.
These results are in accordance with those published by
other authors for L6 muscle cells [19,21,22]. Resistin treat-
ment, however, did not affect the insulin-stimulated con-
tent and recycling of glycogen.
Moreover, in resistin-treated cells, insulin did not in-
crease the PDC flux. After resistin treatment, levels of
Pdk2 mRNA and Pdk4 mRNA were lower, accompanied
with a reduction in levels of Pdha1 mRNA. The reduc-
tion in expression of the main enzyme and key regula-
tors of its activity resulted in a null net effect on the
final flux. The ratio between the PDC and PC fluxes was
also altered, showing reduction in the PC anaplerotic en-
trance into the cycle.
Fluxes through the TCA cycle and acetyl-CoA output
fluxes were not increased, but instead maintained orreduced, by insulin in resistin-treated cells. This lack of
metabolic activation in response to insulin can be ex-
plained by the slight decrease observed in glucose up-
take and the increase of lactate dehydrogenase flux
directed to lactate production, which impaired the in-
crease in the levels of glycolytic intermediates that could
be metabolized through other metabolic pathways. Our
results provide mechanistic explanations for the observa-
tions of Palanivel and co-workers [22], who reported
that the insulin-stimulated oxidation of glucose via the
TCA cycle was reduced by resistin, and that this reduc-
tion would compromise oxidative respiration in the cell.
Conclusions
Several studies have identified positive correlations be-
tween resistin levels and IR in vivo [24] and in vitro
[19-22]. Overall, our results showed that resistin sig-
nificantly alters glucose metabolism in L6E9 myotubes
and their response to insulin. Of the whole set of meta-
bolic changes induced by resistin in L6E9 myotubes, the
imbalance in PDC and PC fluxes as well as the higher
acetyl-CoA output flux for fatty-acid synthesis and other
metabolic processes should be emphasized. Resistin im-
pairs the normal metabolism of insulin, and the metabol-
ism is directed to try to maintain the imbalance between
the PDC and PC fluxes. In this way, L6E9 reduces TCA-
cycle fluxes and acetyl-CoA output fluxes, which leads to
an important metabolic imbalance in the central carbon
metabolic pathways of L6E9 myotubes.
It has been reported that IR in skeletal muscle, liver
and adipose tissue is usually accompanied by glucose in-
tolerance and hypertriglyceridemia [24]. In this way, our
results showed the importance of the balance of PDC
and PC in glucose metabolism.
Our results support the idea that metabolic disorders
such as T2DM are caused by complex multi-molecular in-
teractions that cannot be explained readily by an alteration
in expression of a single gene or gene product, or even al-
teration of a single enzymatic cascade. The robustness of
results obtained on the effects of insulin on L6E9 metabol-
ism found by combining tracer-based metabolomic data
and flux analyses using Isodyn showed that this approach
is a suitable tool to study the effects of hormones on the
central carbon metabolism network in myocytes.
Methods
Cells and reagents
Myoblastic cell line L6E9 was kindly provided by
Dr. Nadal-Ginard (Harvard University, Boston, MD, USA).
Rat recombinant resistin was produced in a HEK293 cell
line. The purity of resistin was controlled by sodium dode-
cyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE)
and estimated to be >99%. Biological activity was validated
as described [42]. Resistin was tested for endotoxin using a
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Nova científica, Madrid, Spain). This assay indicated low
levels of endotoxins (0.0015 EU/mL) at the final concentra-
tion used, which is below current USA Food and Drug
Administion (FDA) limits that require eluates from
medical devices to be <0.5 EU/mL. [1,2-13C2]-D-glucose
and [U-13C-2H7]-D-glucose were purchased from Isotec
(Miamisburg OH, USA) and 2-deoxy-D-[2,6-3H]-glu-
cose (2-DG) from GE Healthcare (Barcelona, Spain).
Conditions for cell culture and incubation
Myoblastic cell line L6E9 was grown as described [38].
For biochemical and mass isotopomer assays, L6E9 myo-
blasts were seeded at 104 cells/cm2 in 60-mm diameter
dishes with 4 mL Dulbecco’s modified Eagle medium
(DMEM) without glucose or glutamine (Biological In-
dustries, Kibbutz Beit Haemek, Israel) supplemented
with 10% heat-inactivated foetal bovine serum (FBS)
(Life Technologies, Madrid, Spain), 10 mM glucose, 4 mM
asparagine and 5% penicillin/streptomycin (Sigma–Aldrich,
Saint Louis MO, USA). Cell differentiation was induced by
lowering FBS to a final concentration of 2% when myo-
blasts were pre-confluent [38].
Cells at day-4 of differentiation were washed four
times in phosphate-buffered saline (PBS) and pre-treated
or not with 100 nM resistin dissolved in DMEM without
FBS and supplemented with 10 mM glucose, 4 mM as-
paragine, 2% HEPES (Sigma–Aldrich) and 1% penicillin/
streptomycin. After 8 h, the medium was replaced by an-
other with the same composition, but now with 10 mM
glucose 50%-enriched in [1,2-13C2]-glucose in the pres-
ence or absence of 100 nM insulin (Sigma–Aldrich). At
the end of 6-h incubation, media were collected and
dishes washed twice with PBS before freezing in liquid
nitrogen. Incubation media and dishes were stored at –
80°C until biochemical and mass isotopomer analyses.Glucose transport assay
To carry out the glucose transport assay, 105 L6E9 cells/
dish were cultured on six-well plates. At day-4 of differen-
tiation, cells were pre-treated or not with 100 nM resistin
for 8 h, as described above. Next, uptake of 100 μCi 2-DG
by myotubes incubated with or without 100 nM insulin
for 30 min was measured as described [38].Biochemical determinations of glucose, lactate and G6P
Concentrations of glucose and lactate in incubation media
at the beginning and end of 6-h incubations were measured
as described previously by spectrophotometric methods
coupled to a Cobas Mira Plus Chemical Analyzer (HORIBA
ABX, Montpellier, France). Intracellular G6P content was
determined by enzymatic means as described [43].Mass isotopomer analyses of lactate, medium and
glycogen glucose, and RNA ribose, and determination of
glycogen content by GC/MS
Mass spectral data were obtained on a QP2010 Shimadzu
Mass Selective Detector connected to a GC-2010 Gas
Chromatograph (Shimadzu, Kyoto, Japan) using helium as
the carrier gas and isobutane 0.0016 Pa as reagent gas in
chemical ionization analyses. The settings were: GC inlet,
250°C for glucose, ribose and deoxyribose, and 200°C for
lactate; transfer line, 250°C; MS source, 200°C. A Varian
VF-5 Capillary Column (30-m length, 250-μm diameter,
0.25-μm film thickness) was used to analyze all compounds.
Glucose from the frozen media was purified using a tan-
dem set of Dowex-1X8/Dowex-50WX8 (Sigma–Aldrich)
ion-exchange columns. The glucose from media was con-
verted to its glucose aldonitrile pentaacetate derivative as
described [43]. Ion clusters around m/z 328 (carbons 1–6
of glucose, chemical ionization) were monitored.
Lactate from the media was extracted with ethyl acet-
ate after acidification with hydrochloric acid (HCl) and
derivatized to its propylamide-heptafluorobutyric form.
Clusters around m/z 328 (carbons 1–3 of lactate, chem-
ical ionization) were monitored [43].
RNA ribose was isolated by acid hydrolysis of cellular
RNA after Trizol purification of cell extracts. Ribose isolated
from RNA was derivatized to its aldonitrile-acetate form
using hydroxylamine in pyridine and acetic anhydride. We
monitored ion clusters around m/z 256 (carbons 1–5 of ri-
bose, chemical ionization) to find the molar enrichment and
positional distribution of 13C labels in ribose as described [44].
Glycogen in frozen cell monolayers from different ana-
lytical conditions was extracted and quantified as de-
scribed [44]. Extraction was done by direct digestion of
sonicated extracts with amyloglucosidase. Mass isotopo-
mer analyses of glycogen glucose was undertaken as de-
scribed above for medium glucose. Measurement of
glycogen content was carried out using the isotopomer
[U-13C-2H7]-glucose as recovery standard and internal
standard quantification procedures. The ion cluster for the
[U-13C-2H7]-glucose of the glucose aldonitrile-pentaacetate
derivative was monitored from m/z 339 to m/z 341.
Spectral data were corrected using regression analysis to
extract natural 13C enrichment from results [45]. Meas-
urement of 13C label distribution determined the different
relative distribution percentages of the mass isotopomers,
m0 (without any 13C labels), m1 (with one 13C), m2 (with
two 13C), etc., which were reported as molar fractions.
Analyses and modelling of data using Isodyn
Transfer of 13C from [1,2-13C2]-glucose medium into intra-
cellular metabolites was simulated by Isodyn, a software
program written in C++ and designed for analyses of data
from stable isotopic tracers [26,33,34]. Latest modifications
of this software have been described in detail [35,36].
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large system of ordinary differential equations describing
the evolution of isotopomer concentrations of metabolites
produced in glycolysis, TCA cycle, and PPP (Figure 1). All
the reactions of the non-oxidative branch catalyzed by
transketolase and transaldolase are accounted for, assum-
ing pentose-5-phosphates to be a single pool. The reac-
tions of the oxidative branch are passed to one reaction
leading from G6P to pentose-phosphates. At this initial
moment, all metabolites (except added labeled substrate)
are assumed to be non-labeled, and the latter is set in ac-
cordance with the known isotopomer composition of the
used labeled substrate. Initial total concentrations of intra-
cellular metabolites are calculated as functions of model pa-
rameters assuming a steady state at the initial moment.
Functions designed especially for each type of reaction (e.g.,
carboxylation, decarboxylation, transketolase-type) simulate
transformation of the carbon skeleton (specific transitions
of labeled carbons), and the production and consumption
rate for each isotopomer of the considered system. These
transformations redistribute 13C isotopes in all metabolites.
Individual rates are computed for each isotopomer, and
these rates determine the values of the derivatives for the
isotopomers. This system is solved using a method of
numerical integration that can be chosen arbitrarily
(Runge-Kutta, BDF, Dassl). Starting from the initial values
corresponding to the experimental conditions of incuba-
tion, Isodyn simulates a real-time course of label propaga-
tion. Experimental and computed data for corresponding
time points are compared. In this way, reaching an isotopic
steady state is not required.
RNA extraction and real-time RT-qPCR gene-expression
analyses
Total RNA was isolated from L6E9 cells using an
RNeasy Mini kit and a QIAcube Automat (Qiagen,
Venlo, the Netherlands). RNA integrity was checked by
capillary electrophoresis (Experion; Bio-Rad, Hercules,
CA, USA). Concentrations were checked with Ribogreen
(Molecular Probes, Eugene, OR, USA) and a Victor-X5
Multilabel Reader (PerkinElmer, Waltham, MA, USA).
Labelled cDNA was synthesized from 600 ng of total RNA
using SuperScript-II, reverse transcriptase and random
hexamers (Life Technologies, Madrid, Spain).
Oligonucleotide sequences for the reverse transcriptase
reaction, synthesized by Eurogentec (Angers, France),
were: pyruvate carboxylase (PC), Pc, rPC-F, TTCCGTGTC
CGAGGTGTAAAG, and rPC-R, CGCTAGGAACTGCT
GGTTGTT; pyruvate kinase muscle isozyme, Pkm2,
rPKm-784F, GAGCAGGACGTGGACATGGT, and rPKm-
864R, CTCTCCCAGGACCTTCCTAACC; pyruvate de-
hydrogenase E1 alpha 1, Pdha1, rNm_001004072.2F,
TTTGTCTTCTGTGCTGGGAGACTG and rNm_00100
4072.2R, GTAGATGGGTGGCTTCAAGTTTGC; pyruvatedehydrogenase kinase isozyme 2, Pdk2, rNm_030872.1F,
CATGGCTAAGCTCCTGTGTGAC, and rNm_030872.1R,
GGACGTAGACCATGTGAATGGG; pyruvate dehydro-
genase kinase isozyme 4, Pdk4, rNm_053551.1F, TGCT
CATGAACCAGCACATCCTC and rNm_053551.1R, TCC
CAATGTGGCTTGGGTTTCC; cytosolic NADP-isocitrate
dehydrogenase, Idh1, rNm_031510.1F, AGACGTCCACCA
ATCCCATTGC, and rNm_031510.1R, TCAAGCTTTG
CTCTGTGGGCTAAC; NADP-dependent malic enzyme,
Me1, rNm_012600.2F, TGCAAGACCATGGTTCCCAG
AC, and rNm_012600.2R, AAGCTAAGCCCAGGGACA
TTAGGG; cytosolic phosphoenolpyruvate carboxykinase
(PEPCK) 1, Pck1, rPEPCK1-2228F, TGGTTCCACTTCG
AGGTCACT, and rPEPCK1-2310R, CAAGTATGTTTT
CTGTGCACTTTAGCT.
Real-time PCR (qPCR) was conducted with a Sybr-
green Master Mix Reagent using Sureprime Core kit
(MP Biomedical, III Kirch, France) in an iCycler (Bio-
Rad, Marnes-la-Coquette, France) apparatus. The stand-
ard curve method was used for relative quantification of
PCR products, and gene expressions normalized to 18S
RNA quantification, which has been found to be a reli-
able internal control gene in our hands and by other
scholars [46-48].
Statistical analyses
Experiments relating to glucose transport were carried out
using three cultures each time for each treatment regimen
and then repeated thrice. Metabolic characterization as-
says were carried out in triplicate and repeated twice.
RNAs for RT-qPCR assays were isolated from three inde-
pendent extracts. Statistical analyses of glucose transport
as well as biochemical and metabolite mass isotopomer
distributions were calculated by two-way ANOVA be-
tween groups. Data for real-time PCR were analyzed by
the one-way ANOVA between groups. Confidence inter-
vals at a confidence level of 95% or 99% (p < 0.05 and p <
0.01, respectively) were taken as indicating significant dif-
ferences in each parameter analyzed. Differences from the
mean were considered significant for p < 0.05.
In the case of the metabolic fluxes estimated using
Isodyn, the difference between calculated and experi-
mental data (χ2) was minimized using a simulated anneal-
ing algorithm. The goodness of best fit (corresponding to
the minimal deviation of calculated isotopomer fractions
from the experimental ones) was checked based on the
value of χ2 and number of degrees of freedom [36]. In
the case that, according to this checking, the fit was
deemed acceptable, the metabolic fluxes corresponding
to the best fit were accepted as consistent with the mea-
sured isotopomer distribution. The confidence intervals
for the fluxes were determined as the upper and lower
limits of fluxes that produced χ2 that was less than the
fixed threshold [36].
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